Yahoo Web Search

  1. Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to ...

  2. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a ...

  3. Allergan plc’s AGN shares declined almost 1% presumably due to the U.S. Supreme Court’s unfavorable ruling in a litigation related to patents covering its blockbuster eye drug, ...

  4. Proxy firms back Allergan in fight against Appaloosa

    Reuters via Yahoo FinanceApr 15 17:59 PM

    Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal ...

  5. Alkermes Reports Positive Data From Schizophrenia Study

    Zacks via Yahoo FinanceApr 10 14:46 PM

    Alkermes plc ALKS announced positive top-line results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a six-month phase IIIb study evaluating ...

  6. Wynn's backtracking illustrates how media leaks of deal talks can test the resolve of potential acquirer. Crown shares jumped as much as 22 percent on the news to A$14.37, close to the $A14.75 ...

  7. Will Ironwood Suffer From Dependence on Linzess' Progress?

    Zacks via Yahoo FinanceApr 05 14:34 PM

    We remind investors that Ironwood co-develops and co-commercializes Linzess and equally shares Linzess U.S. collaboration profits/losses as well as development costs with Allergan AGN ...

  8. This week Pfizer PFE and Teva TEVA gained marketing approval from the European Commission for their new medicines. While Pfizer gained approval for its new lung cancer medicine, Vizimpro, Teva's ...

  9. Allergan Plc said on Monday that proxy advisory firms Institutional Shareholder Services Inc and Glass Lewis & Co had urged its shareholders to vote against hedge fund Appaloosa ...

  10. Editas (EDIT) Inks Cross Licensing Agreement with BlueRock

    Zacks via Yahoo FinanceApr 04 19:39 PM

    Editas Medicine, Inc. EDIT inked a research and cross licensing agreement with BlueRock Therapeutics, LP, to combine their respective genome editing and cell-therapy technologies to discover ...

  1. Ads
    related to Allergan PLC